Why the study?
The study aimed to evaluate the potential effects of beta-arrestin proteins on cardiac substrate metabolism.
Does carvedilol alter cardiac substrate metabolism in mouse hearts and hypertrophied H9c2 cells?
Does carvedilol alter cardiac substrate metabolism in mouse hearts and hypertrophied H9c2 cells?
Carvedilol, acting via β-arrestins, may improve glucose metabolism in hypertrophied cardiac cells by ameliorating glycolysis-glucose oxidation coupling.
Answers are grounded in this paper and cite their sources.
No immediate clinical implications for carvedilol; leaves open β-arrestin effects on metabolism in diseased hearts.
Objective: β-arrestins are G-protein coupled receptor (GPCR) signal regulation proteins. These proteins are involved in metabolic or functional effects of agonist and biased agonist ligands. The aim of this study was to evaluate the potential effects of β-arrestins on cardiac substrate metabolism.Material and Method: To eliminate G-protein effects and to focus specifically on the β-arrestin signal, we used carvedilol, a β-arrestin-biased agonist. Changes in glucose and palmitate oxidation after carvedilol administration were assessed in control mouse hearts. Western blotting was used to evaluate the phosphorylation levels of protein kinase B (Akt), extracellular signal-regulated kinase (ERK) and pyruvate dehydrogenase (PDH) proteins in these hearts. Hypertrophy was induced with phenylephrine in H9c2 cells. Glucose metabolism was measured in cells treated with carvedilol or prazosin using insulinated perfusate.Result and Discussion: Carvedilol did not alter glucose or palmitate oxidation rates in control mouse hearts. However acute administration of carvedilol influenced ERK and PDH phosphorylation in the hearts. In hypertrophied H9c2 cells, carvedilol treatment decreased glycolysis and slightly increased glucose oxidation which resulted in a significant amelioration in glycolysis-glucose oxidation coupling. In conclusion, carvedilol and β-arrestins may improve glucose metabolism.
No takes yet. Share an insight, caveat, or question.
Ciloglu et al. (2026) studied Cardiac energy metabolism and hypertrophy. Carvedilol vs. Control / Prazosin was evaluated on Glucose and palmitate oxidation rates, and phosphorylation levels of Akt, ERK, and PDH.
Synapse has enriched 10 related papers. Consider them for comparative context: